[go: up one dir, main page]

MX2020004151A - Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos. - Google Patents

Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.

Info

Publication number
MX2020004151A
MX2020004151A MX2020004151A MX2020004151A MX2020004151A MX 2020004151 A MX2020004151 A MX 2020004151A MX 2020004151 A MX2020004151 A MX 2020004151A MX 2020004151 A MX2020004151 A MX 2020004151A MX 2020004151 A MX2020004151 A MX 2020004151A
Authority
MX
Mexico
Prior art keywords
environmentally compatible
lipid
inactivation
compatible detergents
enveloped viruses
Prior art date
Application number
MX2020004151A
Other languages
English (en)
Inventor
Jean-Baptiste Farcet
Johanna Kindermann
Björn Tille
Thomas R Kreil
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2020004151A publication Critical patent/MX2020004151A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
    • C11D1/66—Non-ionic compounds
    • C11D1/72—Ethers of polyoxyalkylene glycols
    • C11D1/721—End blocked ethers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2612—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aromatic or arylaliphatic hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G59/00—Polycondensates containing more than one epoxy group per molecule; Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups
    • C08G59/14—Polycondensates modified by chemical after-treatment
    • C08G59/1433—Polycondensates modified by chemical after-treatment with organic low-molecular-weight compounds
    • C08G59/1438—Polycondensates modified by chemical after-treatment with organic low-molecular-weight compounds containing oxygen
    • C08G59/1444—Monoalcohols
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3344—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing oxygen in addition to sulfur
    • C08G65/3346—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing oxygen in addition to sulfur having sulfur bound to carbon and oxygen
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/36—Organic compounds containing phosphorus
    • C11D3/362—Phosphates or phosphites
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/37—Polymers
    • C11D3/3703—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C11D3/3707—Polyethers, e.g. polyalkyleneoxides
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/43—Solvents
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24361—Methods of inactivation or attenuation
    • C12N2770/24363—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polyethers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Detergent Compositions (AREA)

Abstract

La presente invención se refiere a métodos para inactivar un virus envuelto en lípidos usando detergentes compatibles con el medio ambiente, y a métodos para preparar un fármaco biofarmacéutico utilizando detergentes compatibles con el medio ambiente. La invención también proporciona detergentes compatibles con el medio ambiente.
MX2020004151A 2017-10-30 2018-10-30 Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos. MX2020004151A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762578648P 2017-10-30 2017-10-30
US201862687023P 2018-06-19 2018-06-19
PCT/EP2018/079721 WO2019086463A1 (en) 2017-10-30 2018-10-30 Environmentally compatible detergents for inactivation of lipid-enveloped viruses

Publications (1)

Publication Number Publication Date
MX2020004151A true MX2020004151A (es) 2020-08-13

Family

ID=64083092

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004151A MX2020004151A (es) 2017-10-30 2018-10-30 Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.

Country Status (12)

Country Link
US (1) US12258540B2 (es)
EP (1) EP3704178B1 (es)
JP (1) JP7432506B2 (es)
KR (1) KR102651043B1 (es)
CN (1) CN111511800B (es)
AU (1) AU2018357917B2 (es)
CA (1) CA3080656A1 (es)
CO (1) CO2020006181A2 (es)
ES (1) ES2991988T3 (es)
MX (1) MX2020004151A (es)
SG (1) SG11202003793WA (es)
WO (1) WO2019086463A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
EP4192806A1 (en) * 2020-08-05 2023-06-14 Takeda Pharmaceutical Company Limited Methods for preparing and purifying environmentally compatible detergents
WO2024115344A1 (en) 2022-11-29 2024-06-06 Merck Patent Gmbh Method for inactivating enveloped viruses

Family Cites Families (381)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1970578A (en) 1930-11-29 1934-08-21 Ig Farbenindustrie Ag Assistants for the textile and related industries
GB1041554A (en) 1961-10-11 1966-09-07 W J Bush & Company Ltd Improvements in or relating to the dyeing of fibres
DE2154996A1 (de) 1971-11-05 1973-05-10 Bayer Ag Anthrachinonfarbstoffe
JPS527372B2 (es) 1972-07-14 1977-03-02
US4020183A (en) 1974-12-03 1977-04-26 Ortho Pharmaceutical Corporation Nonionic surface active anti-herpes simplex viral agents
SE437329B (sv) 1975-03-14 1985-02-25 Community Blood Council Sett att ur blodserum framstella vaccin mot virushepatit
JPS5265591A (en) 1975-11-26 1977-05-31 Mitsui Petrochem Ind Ltd Purification of polyolefins
DE2605469C3 (de) 1976-02-12 1980-04-10 Behringwerke Ag, 3550 Marburg Verfahren zur Gewinnung eines Spaltprodukts des Tollwut-Virus und dieses enthaltender Impfstoff
US4113712A (en) 1976-03-08 1978-09-12 The Green Cross Corporation HBsAG Particle composed of single polypeptide subunits and the preparation procedure
DE2615161A1 (de) 1976-04-07 1977-10-27 Thiemann Chem Pharm Fab Omega-aminoalkoxy-alkane, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4374127A (en) 1977-09-19 1983-02-15 Merck & Co., Inc. Herpes sub unit vaccine
FI66020C (fi) 1977-09-19 1984-08-10 Merck & Co Inc Foerfarande foer framstaellning av antigeniska immunogeniska subunits av hsv-1 och hsv-2
DE2750045A1 (de) 1977-11-09 1979-05-10 Behringwerke Ag Verfahren zur entfernung von detergentien aus virusantigensuspensionen
ZA792485B (en) 1978-06-07 1980-06-25 New York Blood Center Inc Vaccine for active immunization containing hepatitis b surface and/or e-antigens
DE2847959A1 (de) 1978-11-04 1980-05-14 Behringwerke Ag Verfahren zur isolierung von virusantigenen mittels polyaethylenglykol aus loesungen, die nicht-ionische detergentien enthalten
JPS5940174B2 (ja) 1978-11-16 1984-09-28 財団法人相模中央化学研究所 液体シンチレ−タ−溶液
DK276380A (da) 1979-07-09 1981-01-10 Univ Iowa State Res Found Inc Fremgangsmaade til fremstilling af en vaccine mod infektioes kvaeg-rhinotracheitis
FR2475572A1 (fr) 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
US4452734A (en) 1980-02-11 1984-06-05 Merck & Co., Inc. Herpes subunit vaccine
DE3005495C2 (de) 1980-02-14 1983-03-31 Institut Pasteur, 75724 Paris Herstellung von Fragmenten von Viren mit Lipidhülle und sie enthaltende Arzneimittelzubereitungen
DE3014189A1 (de) 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
ZW9881A1 (en) 1980-06-02 1981-12-23 Hoffmann La Roche Substituted phenoxyaminopropanol derivatives
DE3173208D1 (en) 1980-10-06 1986-01-23 Edward Shanbrom Method of reducing undesirable activities of biological and pharmaceutical products
AR228580A1 (es) 1980-11-25 1983-03-30 Torre Jose Leonardo Procedimiento para inactivar el virus de la fiebre aftosa
JPS5795917A (en) 1980-12-04 1982-06-15 Takeda Chem Ind Ltd Preparation of inactivated sendai virus vaccine
US4327182A (en) 1981-01-22 1982-04-27 Connaught Laboratories Incorporated Purification of influenza sub-unit vaccine
US4975217A (en) 1981-07-20 1990-12-04 Kimberly-Clark Corporation Virucidal composition, the method of use and the product therefor
US4481189A (en) 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4645666A (en) 1982-06-08 1987-02-24 The Regents Of The University Of California Vaccine for bluetongue disease employing platinum compounds
US4511556A (en) 1982-06-10 1985-04-16 The United States Of America As Represented By The Department Of Health And Human Services Inactivation of a lipid virus
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
JPS6041770A (ja) 1983-08-17 1985-03-05 Hitachi Ltd 燃料電池装置
JPS6051120A (ja) 1983-08-31 1985-03-22 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニットワクチン
GB8405521D0 (en) 1984-03-02 1984-04-04 Abm Chemicals Ltd End-blocked nonionic surfactants
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4613501A (en) 1984-12-21 1986-09-23 New York Blood Center, Inc. Inactivation of viruses in labile blood derivatives
US4673733A (en) 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
AT385203B (de) 1985-04-26 1988-03-10 Immuno Ag Verfahren zur herstellung einer fruehsommermeningoenzephalitis-virus (fsme-virus)-vakzine
US4649192A (en) 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
WO1987001128A1 (en) 1985-08-15 1987-02-26 Amgen Lysis method and buffer for extraction of hepatitis b surface antigen from yeast cells
US4789545A (en) 1986-03-31 1988-12-06 New York Blood Center, Inc. Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof
US5426029A (en) 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
DE3704550A1 (de) 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US4943624A (en) 1988-10-28 1990-07-24 Lehigh University Supramolecular surfactants: amphiphilic polymers designed to disrupt lipid membranes
JPH02184842A (ja) 1989-01-11 1990-07-19 Konica Corp 帯電防止性及び塗布性が改良されたハロゲン化銀写真感光材料
CA2007545A1 (en) 1989-01-13 1990-07-13 Yahiro Uemura Production method for protein-containing composition
DE69019141T2 (de) 1989-01-27 1996-01-18 Immunolytics Inc Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie.
JPH02272068A (ja) 1989-04-13 1990-11-06 Mitsubishi Monsanto Chem Co 合わせガラス用着色ポリビニルブチラール中間膜及びその着色剤組成物
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
AU636907B2 (en) 1989-08-29 1993-05-13 Commonwealth Scientific And Industrial Research Organisation Bovine ephemeral fever and antigens and vaccines derived therefrom
GB8919819D0 (en) 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
JPH03168737A (ja) 1989-11-29 1991-07-22 Konica Corp 高コントラストな画像と高品質な網点が得られるハロゲン化銀写真感光材料
US5418130A (en) 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US6251644B1 (en) 1990-04-16 2001-06-26 Baxter International, Inc. Method for inactivating non-enveloped viral contaminants with a photosensitizer by increasing viral permeability to the photosensitizer
US5981163A (en) 1990-05-15 1999-11-09 New York Blood Center, Inc. Process for the sterilization of biological compositions using irradiation and quenchers of type I and type II photodynamic reactions
US5712086A (en) 1990-05-15 1998-01-27 New York Blood Center, Inc. Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactions
US5232844A (en) 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
DE4033446A1 (de) 1990-10-20 1992-04-23 Bayer Ag Impfstoffe gegen equine herpesviren und ihre herstellung
US5314917A (en) 1991-03-22 1994-05-24 E. B. Michaels Research Associates, Inc. Method for inactivating enveloped viruses and sperm
IT1248075B (it) 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
DE4125625C2 (de) 1991-08-02 1999-12-02 Octapharma Ag Glarus Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
CA2096650A1 (en) 1991-09-18 1993-03-21 Keith E. Langley Hepatitis b vaccine formulation incorporating a bile acid salt
FR2686221B1 (fr) 1992-01-22 2000-02-25 Hutchinson Compositions a base d'antiseptiques et leurs applications.
WO1993017723A1 (en) 1992-03-02 1993-09-16 Simmons Paul L Biodegradable surface disinfectant
AU667530B2 (en) 1992-05-28 1996-03-28 New York Blood Center, Inc., The Removal of antibodies from blood-derived compositions while retaining coagulation factors
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
EP0674531A1 (de) 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
EP0683678B1 (de) 1993-02-09 1998-07-15 Octapharma Ag Verfahren zur inaktivierung von viren, die nicht mit lipidhüllen versehen sind
SE9301582D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Purification of plasma proteins
EP0702719B1 (en) 1993-05-28 2005-08-03 New York Blood Center, Inc. Process for the sterilization of biological compositions and the product produced thereby
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
DE4342132C1 (de) 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
US5486293A (en) 1994-03-21 1996-01-23 Hemasure, Inc. Removal of small exogenous molecules from biological fluids
US5514781A (en) 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
US5627080A (en) 1994-07-29 1997-05-06 Beckman Instruments, Inc. Detergent-facilitated immunoassay for the rapid and quantitative assay of pharmacological agents
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
WO1996028025A1 (en) 1995-03-10 1996-09-19 Hemasure, Inc. Inactivation of pathogens in blood and/or blood products using formaldehyde
US5985275A (en) 1995-04-12 1999-11-16 New York Blood Center β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
US6034073A (en) 1995-04-24 2000-03-07 Novavax, Inc. Solvent detergent emulsions having antiviral activity
FI952196A0 (fi) 1995-05-08 1995-05-08 Suomen Punainen Risti Veripalv Framstaellning av immunoglobulin
US6136865A (en) 1995-05-20 2000-10-24 Octapharma Ag Method for reduction of the infectiousness of potentially infectious material
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
DE19528221C2 (de) 1995-08-01 1998-10-22 Blutspendedienst Der Drk Lande Verfahren zur Herstellung eines virussicheren, therapeutischen Präparates aus Humanplasma
DE19544297A1 (de) 1995-11-28 1997-06-05 Behringwerke Ag Verfahren zur Entfernung von aromatischen Verbindungen aus produkthaltigen Lösungen
ES2099678B1 (es) 1995-11-03 1998-02-16 Grifols Grupo Sa Procedimiento para la inactivacion de virus en proteinas.
US5952009A (en) 1996-03-20 1999-09-14 New York Blood Center Methods for preventing the transmission of or treating patients infected with herpesvirus
US5700679A (en) 1996-06-07 1997-12-23 Novavax, Inc. Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity
DE19633684A1 (de) 1996-08-12 1998-02-19 Dirk Dipl Ing Vollenbroich Verfahren zur Inaktivierung von lipidumhüllten Viren
US6440980B1 (en) 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US6194191B1 (en) 1996-11-20 2001-02-27 Introgen Therapeutics, Inc. Method for the production and purification of adenoviral vectors
EP1364944A1 (en) 1997-01-06 2003-11-26 Cerus Corporation Frangible Compounds for Pathogen Inactivation
AT405939B (de) 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
WO1998045311A1 (en) 1997-04-10 1998-10-15 Life Technologies, Inc. Rna isolation reagent and methods
KR20010013377A (ko) 1997-06-04 2001-02-26 데이비드 엠 모이어 마일드한 잔류성 항균 조성물
US7776542B1 (en) 1997-08-04 2010-08-17 Advanced Life Science Institute Methods for the detection of hepatitis B and C viruses
US6162904A (en) 1997-12-24 2000-12-19 Alpha Therapeutic Corporation Manufacturing method for intraveneously administrable immune globulin and resultant product
US6165458A (en) 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
ES2313881T3 (es) 1999-02-05 2009-03-16 MERCK & CO., INC. Formulaciones de vacunas frente al papilomavirus humano.
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
AU5122700A (en) 1999-04-09 2000-11-14 Johns Hopkins University, The Channel forming toxins as antiviral agents
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7087399B1 (en) 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
US7273567B1 (en) 1999-11-24 2007-09-25 Microactive Corp. Energy-activated compositions for controlled sustained release of a gas
US6441144B1 (en) 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
US7279318B1 (en) 1999-06-09 2007-10-09 Hybrid Systems Limited Modification of biological elements
EP1185290A4 (en) 1999-06-15 2005-08-31 Alpha Therapeutic Corp PROCESS FOR PRODUCING INTRAVENOUS IMMUNOGLOBULIN AND RESULTING PRODUCT
SE9902388D0 (sv) 1999-06-23 1999-06-23 Pharmacia & Upjohn Ab Method for purification of proteins
EP1191843A2 (en) 1999-06-23 2002-04-03 The Dial Corporation Antibacterial compositions
WO2000078141A1 (en) 1999-06-23 2000-12-28 The Dial Corporation Antibacterial compositions
US6861397B2 (en) 1999-06-23 2005-03-01 The Dial Corporation Compositions having enhanced deposition of a topically active compound on a surface
WO2001016321A1 (en) 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20050232868A1 (en) 1999-10-19 2005-10-20 The Procter & Gamble Company Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
US6517849B1 (en) 1999-10-19 2003-02-11 The Procter & Gamble Company Tissue products containing antiviral agents which are mild to the skin
US6462180B1 (en) 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
CN1286969C (zh) 1999-12-14 2006-11-29 热生物之星公司 多肽和抗原的稳定稀释剂
MXPA02006540A (es) 1999-12-30 2002-12-09 Kimberly Clark Co Articulo absorbente anitmicrobial y metodos para hacer y usar el mismo.
US6893462B2 (en) 2000-01-11 2005-05-17 Regeneration Technologies, Inc. Soft and calcified tissue implants
US6436885B2 (en) 2000-01-20 2002-08-20 The Procter & Gamble Company Antimicrobial cleansing compositions containing 2-pyrrolidone-5-carboxylic acid
WO2001053444A1 (en) 2000-01-20 2001-07-26 The Procter & Gamble Company Antimicrobial compositions
CA2799545A1 (en) 2000-03-07 2001-09-13 Merck Sharp & Dohme Corp. Adenovirus formulations
DE60137345D1 (de) 2000-04-28 2009-02-26 St Jude Childrens Res Hospital Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus
IL136552A (en) 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
AUPQ846900A0 (en) 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US20020018792A1 (en) 2000-06-30 2002-02-14 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care anti-sebum compositions containing 3,4,4-trichlorocarbanilide
JP2002085057A (ja) 2000-09-12 2002-03-26 Yoshiaki Nagaura ウィルスを不活化する方法
WO2002024244A2 (en) 2000-09-20 2002-03-28 Regeneration Technologies, Inc. Method of preparing and processing transplant tissue
AU2002215914B2 (en) 2000-10-02 2004-08-19 Glaxosmithkline Biologicals S.A. Split enveloped virus preparation
CA2432641A1 (en) 2000-12-14 2002-06-20 Bayer Corporation Method of preparing alpha-1 proteinase inhibitor
CA2438960A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
CN1230526C (zh) 2001-02-27 2005-12-07 成都夸常科技有限公司 一种除去作为病毒灭活剂的有机溶剂和/或去污剂的方法
MXPA03007535A (es) 2001-03-16 2003-12-11 Oncolytics Biotech Inc Metodo para extraer virus de cultivo celular.
US6803041B2 (en) 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
US6635679B2 (en) 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
WO2004030608A2 (en) 2001-06-05 2004-04-15 The Regents Of The University Of Michigan Nanoemulsion vaccines
US7033500B2 (en) 2001-06-25 2006-04-25 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
FR2827610B1 (fr) * 2001-07-17 2005-09-02 Commissariat Energie Atomique Composition de degraissage utilisable pour le degraissage et/ou la decontamination de surfaces solides
CN1208091C (zh) 2001-08-30 2005-06-29 成都夸常科技有限公司 用固定化溶剂或固定化溶剂－去污剂灭活病毒的方法
AU2002347152A1 (en) 2001-12-05 2003-06-17 Cangene Corporation Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
US20030133829A1 (en) 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
GB0201039D0 (en) 2002-01-17 2002-03-06 Incenta Ltd Assay
MXPA04006995A (es) 2002-01-18 2005-07-13 Schering Ag Formulaciones estabilizadas de adenovirus.
US20040142450A1 (en) 2002-05-10 2004-07-22 Seo Sang Heui Lung epithelial cell line for propagating viruses
EP1506287B1 (en) 2002-05-14 2007-04-25 Merck & Co., Inc. Methods of adenovirus purification
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
AR040819A1 (es) 2002-08-08 2005-04-20 Alza Corp Dispositivo de administracion transdermica de vacuna que tiene microproyecciones revestidas
WO2004015004A2 (en) 2002-08-09 2004-02-19 General Motors Corporation Gel coat composition
EP1585964A4 (en) 2002-08-28 2008-07-16 Introgen Therapeutics Inc CHROMATOGRAPHIC METHODS FOR PURIFYING ADENOVIRUSES
EP1558282A4 (en) 2002-10-01 2006-04-19 Chiron Corp COMPOSITIONS AGAINST CANCER AND INFECTION DISEASES AND METHOD OF USE THEREOF
SE0203551D0 (sv) 2002-12-02 2002-12-02 Biovitrum Ab Prothrombin purification
CA2522379C (en) 2003-04-10 2012-10-23 Chiron Corporation The severe acute respiratory syndrome coronavirus
JP5215561B2 (ja) 2003-05-28 2013-06-19 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン及び遺伝子治療のための高力価組換えインフルエンザ・ウイルス
EP1633322A2 (en) 2003-06-04 2006-03-15 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
ES2325584T3 (es) 2003-06-25 2009-09-09 Bn Immunotherapeutics, Inc. Purificacion de variantes de her-2.
US7763452B2 (en) 2003-06-25 2010-07-27 Bn Immunotherapeutics, Inc. Purification of HER-2 variants
PL1651265T3 (pl) 2003-07-24 2008-10-31 Merial Ltd Formulacje szczepionek zawierających emulsję olej w wodzie
AU2004264818B2 (en) 2003-08-01 2011-09-29 Biocon, Ltd Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same
WO2005014648A1 (en) 2003-08-12 2005-02-17 Octapharma Ag Process for preparing an alpha-1-antitrypsin solution
US7037707B2 (en) 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
ATE485519T1 (de) 2003-10-28 2010-11-15 Advanced Life Science Inst Inc Verfahren zum nachweis von hepatitis-c-virus
WO2005049077A2 (en) 2003-11-17 2005-06-02 Regents Of The University Of Minnesota Avian vaccine effective against infectious bursal disease virus
BRPI0416950B8 (pt) 2003-12-01 2021-05-25 Novo Nordisk Healthcare Ag métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida.
KR20060108739A (ko) 2003-12-30 2006-10-18 와이어쓰 개선된 내약성을 가지는 면역원성 조성물 중 소수성단백질의 제제
EP1709162A2 (en) 2004-01-27 2006-10-11 Bharat Biotech International Limited A novel process of hepatitis a vaccine preparation
EP1780269B1 (en) 2004-02-23 2009-07-08 Crucell Holland B.V. Virus purification methods
WO2005107797A1 (en) 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
WO2009131606A2 (en) 2008-02-01 2009-10-29 Belanger Julie M Viral inactivation using crosslinkers and detergents
US8613934B2 (en) 2004-03-22 2013-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cellular and viral inactivation
US20050271711A1 (en) 2004-04-26 2005-12-08 The Procter & Gamble Company Therapeutic antimicrobial compositions and methods
TWI363759B (en) 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
JP5112060B2 (ja) 2004-06-29 2013-01-09 リライアンス ライフ サイエンシーズ プライベイト リミテッド ウイルス安全性生物学的流体の調製のための方法
US20080090222A1 (en) 2004-06-30 2008-04-17 Terumo Kabushiki Kaisha Virus-Inactivated Hemoglobin And Method Of Producing The Same
JP2008512443A (ja) 2004-09-09 2008-04-24 カイロン ベーリング ゲーエムベーハー アンド カンパニー インフルエンザワクチンに関連する潜在的医原性リスクの減少
EP2923711A1 (en) 2004-11-03 2015-09-30 Novartis Vaccines and Diagnostics, Inc. Influenza vaccination
JP2008518632A (ja) 2004-11-03 2008-06-05 イントロゲン セラピューティックス， インコーポレイテッド アデノウイルスベクターの製造および精製のための新規方法
AU2005229674B2 (en) 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
EP1830638A2 (en) 2004-12-09 2007-09-12 The Dial Corporation Compositions having a high antiviral and antibacterial efficacy
CA2588802A1 (en) 2004-12-09 2006-06-15 The Dial Corporation Compositions having a high antiviral and antibacterial efficacy
EP1685852A1 (en) 2005-02-01 2006-08-02 Fondation pour la Recherche Diagnostique Set of disposable bags for viral inactivation of biological fluids
MX2007010971A (es) 2005-03-08 2007-09-19 Pharmacia & Upjohn Co Llc Composiciones de anticuerpo anti-citla-4.
NZ561822A (en) 2005-03-23 2010-04-30 Glaxosmithkline Biolog Sa Multivalent influenza virus vaccine
US20070037192A1 (en) 2005-07-25 2007-02-15 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
US20070036831A1 (en) 2005-08-09 2007-02-15 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
WO2007022718A1 (en) 2005-08-25 2007-03-01 Chunde Liu Alkyl aryl alkyl alcohols, their derivations and preparation process thereof
EP1951296B2 (en) 2005-11-01 2014-07-23 Novartis Vaccines and Diagnostics GmbH Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
EP1957104B1 (en) 2005-11-04 2012-03-21 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines extemporaneously adsorbed to aluminium adjuvants
CA2628397C (en) 2005-11-04 2013-08-20 Novartis Vaccines And Diagnostics S.R.L. Changing th1/th2 balance in split influenza vaccines with adjuvants
CA2628379A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adminstration routes for priming/boosting with influenza vaccines
AU2006310337B9 (en) 2005-11-04 2013-11-28 Novartis Ag Adjuvanted influenza vaccines including cytokine-inducing agents
AU2006310339B2 (en) 2005-11-04 2013-01-10 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
CN101346152A (zh) 2005-11-04 2009-01-14 诺华疫苗和诊断有限公司 用细胞培养物培养的流感病毒制备含非病毒颗粒抗原的佐剂疫苗
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
US20070128693A1 (en) 2005-12-06 2007-06-07 Advantek Serum Laboratories Limited3/F Method for the inactivation and removal of dengue virus from biological samples
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
ES2439641T3 (es) 2005-12-20 2014-01-24 Bristol-Myers Squibb Company Composiciones y procedimientos de producción de una composición
EP2478916B1 (en) 2006-01-27 2020-04-01 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
US8252339B2 (en) 2006-04-11 2012-08-28 Massachusetts Institute Of Technology Medical treatment applications of swellable and deformable microspheres
US7794755B2 (en) 2006-04-11 2010-09-14 E.I. Du Pont De Nemours And Company Process for preparation of swellable and deformable microspheres
JP5259578B2 (ja) 2006-05-19 2013-08-07 ビロブロック エスアー エンベロープウイルスを不活化させるための組成物
PL2032163T3 (pl) 2006-06-15 2013-06-28 Novartis Ag Wielodawkowa szczepionka przeciwko grypie o małej zawartości adiuwanta
US20080003574A1 (en) 2006-06-28 2008-01-03 Sigma-Aldrich Co. Kits for RNA extraction
JP5639760B2 (ja) 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザワクチン
CN101501696A (zh) 2006-08-14 2009-08-05 麻省理工学院 聚糖数据挖掘系统
KR20090050056A (ko) 2006-08-14 2009-05-19 메사츄세츠 인스티튜트 어브 테크놀로지 헤마글루티닌 폴리펩티드 및 시약 그리고 방법
US20090081193A1 (en) 2006-08-14 2009-03-26 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
BRPI0716536A2 (pt) 2006-09-11 2013-09-24 Novartis Ag produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos
CA2666146A1 (en) 2006-10-10 2008-04-17 Michael Lynch Methods of inactivating viruses
EP2121011B1 (en) 2006-12-06 2014-05-21 Novartis AG Vaccines including antigen from four strains of influenza virus
AU2007334451A1 (en) 2006-12-15 2008-06-26 Merck Sharp & Dohme (Holdings) Pty Ltd. Method for replicating influenza virus in culture
WO2008096093A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses
GB0702385D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702416D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
JP4829828B2 (ja) 2007-03-28 2011-12-07 シスメックス株式会社 血液凝固測定用試薬及び組織因子安定化方法
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
US8747872B2 (en) 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
ES2377167T3 (es) 2007-05-24 2012-03-23 Abbott Laboratories Inmunoensayos que muestran reactividad cruzada reducida con metabolitos de analito de fármacos hidrófobos
AU2008261634B2 (en) 2007-06-12 2014-04-24 Rhodia Inc. Detergent composition with hydrophilizing soil-release agent and methods for using same
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
WO2009029695A1 (en) 2007-08-28 2009-03-05 Baxter International Inc. Method for producing viral vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
NZ586439A (en) 2007-12-24 2012-10-26 Novartis Ag Method for peforming an immunodiffusion assay (SRID) for influenza hemagglutinin antigen based on desorbing the antigen from the aluminium adjuvant salt
EP2238146A4 (en) 2008-01-03 2012-03-21 Massachusetts Inst Technology HEMAGGLUTININE POLYPEPTIDES AND REAGENTS AND METHODS RELATED THEREWITH
KR20100111275A (ko) 2008-01-03 2010-10-14 메사츄세츠 인스티튜트 어브 테크놀로지 유인 인플루엔자 치료제
EP2077118A1 (en) 2008-01-07 2009-07-08 Gwo Rei Biomedical Technology Corp. Clottable concentrate of platelet growth factors and preparation method thereof
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
US20110009520A1 (en) 2008-03-20 2011-01-13 Figuly Garret D Dimensionally stable, shaped articles comprised of dried, aggregated, water-swellable hydrogel microspheres and method of making same
US9144606B2 (en) 2008-04-21 2015-09-29 Nanobio Corporation Nanoemulsion influenza vaccine
CA2722558A1 (en) 2008-04-25 2009-10-29 Id Biomedical Corporation Of Quebec Methods for preparing immunogenic compositions
GB0905570D0 (en) 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
ES2391613T3 (es) 2008-06-24 2012-11-28 Octapharma Ag Un procedimiento para purificar el factor de coagulación VIII
NZ590257A (en) 2008-07-18 2012-08-31 Grifols Therapeutics Inc Method of preparing alpha-1 proteinase inhibitor
CA2738245A1 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
CN102257006A (zh) 2008-10-20 2011-11-23 雅培制药有限公司 使用a蛋白亲和层析分离和纯化抗体
KR20110095277A (ko) 2008-10-31 2011-08-24 바이오메리욱스, 인코포레이티드. 라만 분광법을 이용하여 미생물을 분리, 특성규명, 및/또는 동정하는 방법
US10167494B2 (en) 2008-10-31 2019-01-01 Biomerieux, Inc. Method for detection, characterization and/or identification of microorganisms in a sealed container
US8647835B2 (en) 2008-10-31 2014-02-11 BIO MéRIEUX, INC. Methods for separation, characterization and/or identification of microorganisms using spectroscopy
AU2009320337B2 (en) 2008-10-31 2014-07-31 Biomerieux, Inc. Methods for separation, characterization and/or identification of microorganisms using spectroscopy
CN102317789B (zh) 2008-10-31 2014-08-27 生物梅里埃公司 利用质谱法分离、表征和/或鉴定微生物的方法
EP2364447B1 (en) 2008-10-31 2019-06-12 Biomerieux, Inc Method for the identification of microorganisms
JP2012507272A (ja) 2008-11-05 2012-03-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
CA2742817A1 (en) 2008-11-20 2010-05-27 Biogen Idec Ma Inc. Arginine inactivation of viruses
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
KR20110132373A (ko) 2009-02-10 2011-12-07 노파르티스 아게 유행병-연관 주에 대한 인플루엔자 백신 요법
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
CA2754826A1 (en) 2009-03-06 2010-09-10 Mount Sinai School Of Medicine Live attenuated influenza virus vaccines comprising microrna response elements
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
WO2010128396A2 (en) 2009-05-08 2010-11-11 Novartis Ag Generic assays for detection of influenza viruses
US8445270B2 (en) 2009-05-12 2013-05-21 Transgene S.A. Immortalized avian cell lines and use thereof
JP5836266B2 (ja) 2009-05-21 2015-12-24 ノバルティス アーゲー 非内因性ｐｏｌＩプロモーターを使用した逆遺伝学
US8546548B2 (en) 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
EA201171491A1 (ru) 2009-05-29 2012-07-30 Новартис Аг Анализы гемагглютининов вируса гриппа
EP2442827B1 (en) 2009-06-16 2016-01-06 The Regents of the University of Michigan Nanoemulsion vaccines
JP5886194B2 (ja) 2009-07-02 2016-03-16 マサチューセッツ インスティテュート オブ テクノロジー インフルエンザ感染の診断および／または処置のための組成物および方法
WO2011011753A1 (en) 2009-07-23 2011-01-27 Baxter International Inc. Manufacture of factor h (fh) and fh-derivatives from plasma
EP2459722B1 (en) 2009-07-31 2017-09-06 Seqirus UK Limited Reverse genetics systems
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
AU2010293902A1 (en) 2009-09-10 2012-03-22 Novartis Ag Combination vaccines against respiratory tract diseases
MX2012002814A (es) 2009-09-10 2012-08-17 Merial Ltd Nuevas formulaciones de vacuna que comprenden adyuvantes que contienen saponina.
CA2778332A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
US20120240937A1 (en) 2009-12-09 2012-09-27 Glaxosmithkline Llc Coating for Latex Articles
IT1397061B1 (it) 2009-12-28 2012-12-28 Kedrion Spa Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale.
CN101732711A (zh) 2009-12-31 2010-06-16 中国人民解放军军事医学科学院微生物流行病研究所 一种喷鼻免疫流感五价或多价灭活疫苗的制备及其应用
EP2536425B1 (en) 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
ES2596727T3 (es) 2010-03-30 2017-01-11 Octapharma Ag Procedimiento de purificación de un factor proteico de crecimiento G-CSF
EP2553095B1 (en) 2010-03-30 2016-10-12 Octapharma AG A process for purifying vitamin K dependent proteins such as coagulation factor IX
CN102858961A (zh) 2010-05-03 2013-01-02 葛兰素史密丝克莱恩生物有限公司 新方法
JP6072677B2 (ja) 2010-05-06 2017-02-01 ノバルティス アーゲー 微生物の不活化のための有機ペルオキシド化合物
EP2571520B1 (en) 2010-05-21 2018-04-04 Seqirus UK Limited Influenza virus reassortment method
EP2389942B1 (en) 2010-05-25 2013-01-23 GwoWei Technology Co., Ltd. Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
AU2011262309B2 (en) 2010-06-01 2015-08-13 Seqirus UK Limited Concentration of influenza vaccine antigens without lyophilization
KR20130093607A (ko) 2010-07-23 2013-08-22 백스터 인터내셔널 인코포레이티드 혈장으로부터 인터-알파-억제제 단백질 (iaip)의 제조
WO2012032482A1 (en) 2010-09-07 2012-03-15 Novartis Ag Generic assays for detection of mammalian reovirus
AU2011305371B2 (en) 2010-09-21 2015-05-21 Massachusetts Institute Of Technology Human-adapted HA polypeptides, vaccines, and influenza treatment
US10226527B2 (en) 2010-10-04 2019-03-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
CA2815275C (en) 2010-10-27 2023-09-19 Glaxosmithkline Biologicals S.A. Immunogenic compositions derived from shigella
JP2014511119A (ja) 2010-11-02 2014-05-08 インムノライフ，エセ．ア．デ セー．ウーベ． Ｈ１ｎ１亜型インフルエンザパンデミックウイルスに対する新型ワクチン
MX2013004975A (es) 2010-11-02 2014-01-17 Opko Pharmaceuticals Llc Vacunas novedosas contra el virus pandémico de la influenza a/h1n1.
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
CN102464974B (zh) 2010-11-17 2013-08-07 中国石油化工股份有限公司 可大幅度提高原油采收率的组合物及其制备方法
US20120208982A1 (en) 2010-12-15 2012-08-16 Baxter Healthcare S.A. Viral Inactivation Using Improved Solvent-Detergent Method
IL210162A0 (en) 2010-12-21 2011-03-31 Omrix Biopharmaceuticals Viral inactivated platelet extract, use and preparation thereof
US20120219636A1 (en) 2011-02-28 2012-08-30 The Ohio State University Enhanced removal of viruses from fresh produce
KR20120098202A (ko) 2011-02-28 2012-09-05 (주)차바이오앤디오스텍 자하거 추출물 및 자하거 추출물 제조 방법
DK2681553T3 (en) 2011-03-04 2017-08-28 Baxalta GmbH PROCEDURE FOR DETERMINING POLYSORBATE
US9017950B2 (en) 2011-03-18 2015-04-28 Luminescent MD, LLC Method for enhancing enzyme assays
PL2697369T3 (pl) 2011-03-25 2018-12-31 F.Hoffmann-La Roche Ag Nowe sposoby oczyszczania białek
AU2012260807B2 (en) 2011-05-26 2016-05-12 Glaxosmithkline Biologicals Sa Inactivated Dengue virus vaccine
WO2013006569A2 (en) 2011-07-01 2013-01-10 The Regents Of The University Of California Herpes virus vaccine and methods of use
CA2840982C (en) 2011-07-06 2022-06-07 Vira BITKO Human respiratory syncytial virus vaccine
EP2734280A4 (en) 2011-07-22 2015-04-15 Bio Merieux Inc METHOD AND NECESSARY INSULATING MICROORGANISMS OF A CULTURE
WO2013019964A1 (en) 2011-08-02 2013-02-07 Baxter International, Inc. Systems and methods to increase protein yield from recombinant manufacturing processes
US9561271B2 (en) 2011-09-09 2017-02-07 Nanobio Corporation Nanoemulsion respiratory syncytial virus (RSV) subunit vaccine
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
AU2012324398A1 (en) 2011-10-20 2014-05-01 Seqirus UK Limited Adjuvanted influenza B virus vaccines for pediatric priming
WO2013135274A1 (en) 2012-03-13 2013-09-19 Intercell Ag Aluminium compounds for use in therapeutics and vaccines
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
ES2628301T3 (es) 2012-03-02 2017-08-02 Seqirus UK Limited Recombinación de virus de gripe
GB201205189D0 (en) 2012-03-23 2012-05-09 Glaxosmithkline Biolog Sa Novel medical use
US20130315955A1 (en) 2012-04-13 2013-11-28 Protein Sciences Corporation Stability and potency of hemagglutinin
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
CN102614508B (zh) 2012-04-28 2013-10-30 长春生物制品研究所有限责任公司 一种人用流感病毒裂解疫苗的病毒裂解灭活方法
ES2895173T3 (es) 2012-06-29 2022-02-17 Emd Millipore Corp Métodos para inactivar virus durante un proceso de purificación de proteínas
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
US9353165B2 (en) 2012-07-25 2016-05-31 Grifols, S.A. Purification of cell culture derived alpha1 protease inhibitor
WO2014025771A2 (en) 2012-08-06 2014-02-13 Biogen Idec Ma Inc. Methods and compositions for inactivating enveloped viruses
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
WO2014071344A2 (en) 2012-11-05 2014-05-08 Medimmune, Llc Method of isolating synagis® in the absence of benzonase
EP2925356A2 (en) 2012-12-03 2015-10-07 Novartis AG Reassortant influenza a viren
CN102943000A (zh) 2012-12-17 2013-02-27 江南大学 一种活性氧增彩洗衣液
RU2015132962A (ru) 2013-01-10 2017-02-14 Новартис Аг Иммуногенные композиции на основе вируса гриппа и их применение
WO2014115104A1 (en) 2013-01-23 2014-07-31 Novartis Ag Influenza virus reassortment
TWI641382B (zh) 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
CN105263954B (zh) 2013-02-07 2019-12-03 麻省理工学院 H5流感的人类适应
US9393252B2 (en) 2013-03-12 2016-07-19 Ecolab Usa Inc. Aromatic carboxylic acids in combination with aromatic hydroxyamides for inactivating non-enveloped viruses
EP2968512A2 (en) 2013-03-13 2016-01-20 Novartis AG Influenza b virus reassortment
WO2014167582A2 (en) 2013-03-31 2014-10-16 Ella Foundation Vaccine composition for prophylaxis in ruminants
WO2015126462A1 (en) 2014-02-19 2015-08-27 Materia, Inc. Preparation of surfactants via cross-metathesis
US9758445B2 (en) 2013-04-09 2017-09-12 Materia, Inc. Preparation of surfactants via cross-metathesis
US10301359B2 (en) 2013-04-30 2019-05-28 Massachusetts Institute Of Technology Human adaptation of H3 influenza
FR3005265B3 (fr) 2013-05-06 2017-01-27 Novartis Ag Reassortiment du virus de la grippe
BR112015028314A2 (pt) 2013-05-10 2017-09-19 Steinman Lawrence Prevenção do risco de narcolepsia em vacinas para gripe
US10526375B2 (en) 2013-06-05 2020-01-07 Massachusetts Institute Of Technology Human Adaptation of H7 HA
AU2014276418A1 (en) 2013-06-06 2016-01-21 Novartis Ag Influenza virus reassortment
EP3043813B1 (en) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
CN103392691B (zh) 2013-08-14 2015-09-23 北京瑞健高科生物科技有限公司 一种生物组织处理、灭菌及保存的容器和方法
EP3039161B1 (en) 2013-08-30 2021-10-06 Personalis, Inc. Methods and systems for genomic analysis
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
NO346902B1 (en) 2013-09-30 2023-02-20 Resman As Chemical compounds
US20150118249A1 (en) 2013-10-24 2015-04-30 Medimmune, Llc Stable, Aqueous Antibody Formulations
HRP20240222T1 (hr) 2013-11-15 2024-04-26 F. Hoffmann - La Roche Ag Postupci inaktivacije virusa korištenjem ekološki prihvatljivih deterdženata
EP3068791B1 (en) 2013-11-15 2020-07-29 Novartis AG Removal of residual cell culture impurities
EP3076993A1 (en) 2013-12-05 2016-10-12 Janssen Vaccines & Prevention B.V. Process for preparing influenza vaccines
WO2015100344A1 (en) 2013-12-27 2015-07-02 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
TWI671312B (zh) 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
NZ760783A (en) 2014-01-21 2023-07-28 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
DK3131589T3 (da) 2014-04-15 2023-08-07 Boehringer Ingelheim Int Fremgangsmåde og anvendelse til fortløbende inaktivering af en virus under tilvejebringelse af et biologisk produkt
EA201692568A1 (ru) 2014-06-13 2017-05-31 Санта Мария Биотерапевтикс, Инк. Составы с полипептидами-рецепторами и связанные с ними способы
US10124056B2 (en) 2014-08-18 2018-11-13 Sanofi Pasteur Inc. Alkylated influenza vaccines
CN104211943B (zh) 2014-09-17 2016-08-24 南京卡邦科技有限公司 一种制备分离单分散聚乙二醇的方法
CN104324370B (zh) 2014-09-30 2019-12-20 普莱柯生物工程股份有限公司 疫苗组合物及其制备方法和应用
PT3209767T (pt) 2014-10-21 2020-11-09 Gennova Biopharmaceuticals Ltd Um novo processo de purificação para isolamento e produção comercial de tnk-tpa recombinante (tenecteplase)
MD3227325T2 (ro) 2014-12-01 2024-09-30 Ferring Bv Compoziții de inhibitor selectiv trans-semnalizare de IL-6
DK3226888T3 (da) 2014-12-01 2021-07-12 Ferring Bv Administration af en selektiv inhibitor af il-6-trans-signalering
CA2970158A1 (en) 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
CN107847579A (zh) 2014-12-19 2018-03-27 俄勒冈健康与科学大学 人和禽h5n1流感的计算优化的广泛反应性抗原的协同共同给药
CN104548084A (zh) 2014-12-30 2015-04-29 吕宏亮 一种广谱粘膜免疫防控猪繁殖与呼吸综合症的疫苗组合物及其应用
JP6862348B2 (ja) 2015-03-12 2021-04-21 メディミューン，エルエルシー アルブミン融合タンパク質を精製する方法
MX2017012389A (es) 2015-03-27 2018-09-19 Cadila Healthcare Ltd Vacuna del virus de la parotiditis recombinante jeryl lynn2.
JP6651300B2 (ja) 2015-04-23 2020-02-19 山本化成株式会社 フタロシアニン化合物、これを含有する近赤外線カットフィルタ
WO2016196846A2 (en) 2015-06-02 2016-12-08 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
EP3307761A4 (en) 2015-06-09 2019-01-16 Sanofi Pasteur Inc. PROCESS FOR OPTIMIZING NUCLEOTIDE SEQUENCES COPING MANIPULATED INFLUENZA PROTEINS
EP3314020A1 (en) 2015-06-29 2018-05-02 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
WO2017053374A1 (en) 2015-09-21 2017-03-30 Oregon Health & Science University Design and characterization of influenza vaccines
US20200237898A1 (en) 2015-09-21 2020-07-30 Oregon Health & Science University Vaccines intelligently produced by epitope recombination (viper) for influenza
EP3426683A1 (en) 2016-03-11 2019-01-16 Boehringer Ingelheim International GmbH Methods for continuously inactivating a virus during manufacture of a protein
CN106187828A (zh) 2016-07-19 2016-12-07 南通市晗泰化工有限公司 烷基苯甲醇聚氧乙烯醚琥珀酸二钠盐及其制备方法
CN106117264A (zh) 2016-07-19 2016-11-16 南京林业大学 烷基苯甲醇聚氧乙烯醚磷酸铵及其制备方法
CN106187714A (zh) 2016-07-19 2016-12-07 南通市晗泰化工有限公司 烷基苯甲醇聚氧乙烯醚及其制备方法
CN106187713A (zh) 2016-07-19 2016-12-07 南通市晗泰化工有限公司 烷基苯甲醇聚氧乙烯醚羟丙基烯丙基醚及衍生物及其制备方法
CN106187833A (zh) 2016-07-19 2016-12-07 南通市晗泰化工有限公司 烷基苯甲醇聚氧乙烯醚硫酸铵及其制备方法
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
CN109400449B (zh) 2018-09-29 2022-06-10 中国日用化学研究院有限公司 一种制备烷基苯基醇聚氧乙烯醚的方法

Also Published As

Publication number Publication date
SG11202003793WA (en) 2020-05-28
US20210032567A1 (en) 2021-02-04
ES2991988T3 (es) 2024-12-05
RU2020117357A (ru) 2021-12-01
RU2020117357A3 (es) 2022-03-30
AU2018357917A1 (en) 2020-05-07
EP3704178A1 (en) 2020-09-09
JP2021501163A (ja) 2021-01-14
KR20200071127A (ko) 2020-06-18
CA3080656A1 (en) 2019-05-09
BR112020008414A2 (pt) 2020-11-17
EP3704178B1 (en) 2024-07-24
AU2018357917B2 (en) 2024-08-01
WO2019086463A1 (en) 2019-05-09
US12258540B2 (en) 2025-03-25
KR102651043B1 (ko) 2024-03-22
JP7432506B2 (ja) 2024-02-16
CN111511800B (zh) 2023-11-28
CN111511800A (zh) 2020-08-07
CO2020006181A2 (es) 2020-10-30

Similar Documents

Publication Publication Date Title
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
CL2020000912A1 (es) Compuestos químicos
MX2020012132A (es) Compuestos de azapiridona y usos de los mismos.
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
EA201890736A1 (ru) Модуляторы корового белка вируса гепатита b
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
EA201790630A1 (ru) Способы получения рибозидов
CL2016001936A1 (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
UY34780A (es) Vectores virales para el tratamiento de distrofia retiniana
MX2015016755A (es) Reagrupamiento del virus de influenza.
UY35362A (es) Compuestos terapéuticos
CL2013003313A1 (es) Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8.
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
MX372963B (es) Reordenamiento del virus de influenza b.
MX2019002438A (es) Compuestos triciclicos fusionados de piridazinona utiles para tratar infecciones de orthomyxovirus.
MX377357B (es) Compuestos para dispositivos ópticamente activos.
CO2020006181A2 (es) Detergentes compatibles con el medio ambiente para la inactivación de virus envueltos en lípidos
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
MX393092B (es) Bis-compuestos para dispositivos opticamente activos.
CO2020001426A2 (es) Método para incubar líquidos e inactivar virus
CL2017000151A1 (es) Derivados de piridona